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ABSTRACT
Considering the growing availability of ultrasound diagnostic methods in gynecology, its role in the infertility setting is 
increasing. In this review, we present an up-to-date ultrasound based diagnostic scheme in infertility workup comprising 
the evaluation of ovarian anatomy and function, uterine exploration, as well as tubal patency. The possibility of performing 
the vast majority of infertility diagnostics by ultrasound in the ambulatory settings is not only attractive and beneficial to 
patients, but also to health care system. Thus, it is vital for gynecologists to implement modern non-invasive ultrasound 
modalities in their everyday practice.
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INTRODUCTION
Imaging diagnostics is the essential part of contemporary 
medicine. The ultrasound-based examination plays a special 
role in gynecology and its use has been rising, particularly 
in infertility workup. Increasingly, ultrasound examinations 
allow to get a diagnosis without introducing invasive pro-
cedure. Patients are properly qualified to have invasive 
procedures and, owing to modern ultrasound modalities, 
hysteroscopy and laparoscopy can be applied rather for 
treatment than simply for diagnosing [1]. 
In this literature review, we aimed to present an up- 
-to-date ultrasound based diagnostic scheme in infertility 
workup based on records concerning this field published in 
English in Pubmed/MEDLINE database from January 2010 to 
November 2020.
Ultrasound assessment of the ovaries
Besides hormonal methods, cycle monitoring and 
counting antral follicles by ultrasound are accepted, 
complementary methods to evaluate ovarian reserve and 
function [2]. They are offered to women of reproductive 
age for various reasons such as in subfertility and ovulatory 
dysfunction, in infertility and assisted reproduction workup 
or in predicting the risk of menopause. 
The antral follicle count (AFC) includes a total number of 
antral follicles seen in both ovaries measuring 2 to 10 mm 
responsive to follicle-stimulating hormone (FSH) that can be 
recruited to maturation. Follicles > 10 mm are referred to 
as ‘dominant’ ones. Total AFC (follicles from both ovaries) is 
used frequently in assisted reproduction centers to predict 
ovarian response to gonadotropin stimulation, whereas 
the follicle number per ovary (FNPO) is more useful in gy-
necological practice to assess functional ovarian reserve [3]. 
The suggestion of how to interpret follicle count according 
to Consensus Opinion by Coelho Neto et al. [3] is presented 
in Table 1. 
It has been suggested to examine AFC in the early follicular 
phase of the menstrual cycle, whereas an ultrasound between 
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days 10 to 12 determines whether a ‘good’ dominant follicle 
is present and shows the endometrial response to follicular 
development [1]. Scans should be transvaginal (TVS) and with 
a minimum frequency of 7 MHz. Hormonal contraceptives and 
gonadotropin-releasing hormone agonists may reduce the 
quantity of follicles seen on an ultrasound, AFC is therefore 
preferentially measured during a natural cycle or after two to 
three months without hormone use. The observer-depend-
ence is believed to be a disadvantage of this technique. How-
ever, accuracy increases with the operator’s skill [3, 4]. 
Both two-dimensional (2D) and three-dimensional 
(3D) ultrasounds may be employed to perform AFC. 
On a 2D ultrasound, follicles are counted using either re-
al-time imaging or stored cine-loops. When using a 3D ultra-
sound, the most common technique is to count the follicles 
manually in the multi-planar mode. However, there are like-
wise rendered modes to perform it semi-automatically, for 
example sonography-based automated volume calculation 
(sonoAVCTM by GE Healthcare, United States or syngo® Auto 
Follicle by Siemens Healthcare GmbH, Erlagen, Germany) [4] 
(Fig. 1A–B). Further research should include the reproduc-
ibility of new volume modalities available for follicle count. 
Currently, anti-Mullerian Hormone (AMH) is considered as 
the most reliable marker for ovarian reserve and it is also rec-
ommended by Polish Society of Reproductive Medicine and 
Embryology (PTMRiE) in basic female fertility assessment [5]. 
It has been shown that there is a strong positive correlation 
between serum AMH level and AFC. The use of AMH com-
bined with AFC may improve ovarian reserve evaluation [6]. 
Ultrasound assessment of the uterine cavity
The assessment of the uterine cavity is another routine 
examination performed in patients with subfertility and 
infertility. In the past, laparoscopy (to assess the outer shape 
of the uterus) with hysteroscopy (to assess the cavity) were 
the gold test in diagnosis of congenital uterine anomalies, 
however, now considering the evidence ultrasound-based 
techniques seem to play a crucial role [7]. 
Basic 2D ultrasounds should be employed as a screen-
ing tool to assess the uterine cavity and secondary uterine 
pathologies such as polyps, myomas, uterine adhesions, or 
adenomyosis [8]. A 2D transvaginal ultrasound performed 
by an expert in the field, with standardized evaluation of the 
uterus scans in mid-sagittal and transverse plane, was ob-
served to be highly accurate (84–90.6%) in the differentiation 
of arcuate, bicornuate, and septate uteri compared to lapa-
roscopy with hysteroscopy [8]. Compared with conventional 
2D ultrasounds, 3D volume imaging has a higher diagnostic 
accuracy in detecting uterine anomalies (97.1–100%) [7]. 
Table 1. Suggestion of how to interpret follicle count according to Consensus Opinion adapted from Coelho Neto et al. [3]
Nomenclature Total AFC Interpretation for ovarian stimulation
Very low number of recruitable follicles 0–4 Very high risk of poor response to ovarian stimulation
Low number of recruitable follicles 5–8 High risk of poor response to ovarian stimulation
Normal number of recruitable follicles 9–19 Normal response to ovarian stimulation expected 
Large number of recruitable follicles ≥ 20 High risk of excessive ovarian response to ovarian stimulation
Nomenclature FNPO Interpretation in clinical practice
Low follicle count 1–3 Low ovarian reserve
Normal follicle count 4–24 Normal ovarian reserve
High follicle count ≥ 25 Polycystic pattern
AFC — antral follicle count; FNPO — follicle number per ovary
Figure 1. Ovaries visualised with sonoAVC; A. Ovary with several 
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Coronal view, which is pivotal for the diagnosis, is rendered 
from a 3D dataset acquired, either on the ultrasound ma-
chine or on the personal computer. The reproducibility of 3D 
ultrasound is high, that is why it is recommended to be the 
first diagnostic step in the assessment of the uterine cavity 
[8, 9]. To obtain good quality images with clear margins be-
tween endometrium and myometrium, the exam should be 
performed in the second phase of the menstrual cycle [10]. 
A 3D TVS combined with Power Doppler also has value for 
the differential diagnosis of endometrial lesions among infer-
tile women. Endometrial thickness and volume were larger 
among women with endometrial polyps and hyperplasia, 
whereas endometrial vascularization index, flow index, and 
vascularization flow index were lower among women with 
intrauterine adhesions [11].
According to The European Society of Human Repro-
duction and Embryology (ESHRE) and European Society for 
Gynaecological Endoscopy (ESGE) consensus on diagnosis 
of female genital anomalies magnetic resonance imaging 
(MRI) or eventually endoscopic evaluation are recommend-
ed for the subgroup of patients with suspected complex 
anomalies, diagnostic dilemmas or in case of poor quality 
of ultrasound visualization [9]. MRI is advised as a first line 
diagnostic procedure in the case of adolescents [9]. 
Sonohysterography
Sonohysterography or saline infusion sonohys-
terography (SIS) is minimally invasive, outpatient and 
low-cost method to visualize the endometrial cavity in 
more detail than is possible with routine transvaginal 
ultrasounds. Once the uterine cavity is filled with sterile 
fluid (e.g., saline infusion), a real-time 2D scanning of the 
uterine cavity is completed. Additional techniques, such 
as 3D ultrasound, may be used for acquiring coronal view 
[12] (Fig. 2A). There are also novel, worth mentioning 
modalities assessing uterine cavity volume and shape us-
ing automatic volume calculation software [13] (Fig. 2B). 
The main indication for 3D-SIS is verification of doubtful 
3D-TVS images [8]. Moreover, 2D and 3D-SIS are useful in 
the diagnosis of diseases closely related to infertility, in 
particular myomas, endometrial polyps and Asherman’s 
syndrome [14, 15]. It allows the preoperative evaluation 
of benign intracavitary lesions [16]. Sonohysterography 
also plays an important role in secondary fertility investi-
gation due to cesarian scar pregnancy. Recent studies re-
vealed that 3D-SIS is superior in evaluation of the residual 
myometrial thickness and niche width providing better 
characterization of the scar niche [17]. It is suggested 
that uterine niches should always be assessed by SIS, 
because assessment of niche morphology is commonly 
dependent on the presence of natural fluids in a niche, 
which is highly changeable during the menstrual cycle. 
Using only 2D TVS may underestimate the prevalence of 
scar pregnancy defect [18].
According to Ludwin  et al. [8],  3D-SIS  is the only 
ultrasound method which provides results consistent with 
hysteroscopy performed with laparoscopy, considered as 
the gold standard, in the differential diagnosis of septate, 
bicornuate and arcuate uteri. SIS showed also significantly 
higher accuracy (100.0%) compared to diagnostic hyster-
oscopy without laparoscopy (80.7%) in the differential di-
agnosis of the aforementioned pathologies [19]. It seems 
that 3D-SIS should be preferred for a final differential diag-
nosis of the most frequent uterine anomalies if these con-
ditions are not accompanied by other medical indications. 
The authors emphasize, that hysteroscopy without laparos-
copy, which is often performed in these cases, is a subop-
timal, poorly reproducible method to differentiate septate 
and bicornuate uterus, because the outer shape of the uterus 
cannot be verified [8]. PTMRiE recommends performing di-
agnostic laparoscopy in patients suspected of pelvic lesions 
or having risk factors for tubal occlusion, so that the patient 
could benefit from the surgery [5]. According to Polish Soci-
ety of Gynecologists and Obstetricians guidelines regarding 
hysteroscopy, it should be offered routinely in case of intra-
cavitary lesions detected on ultrasound, abnormal uterine 
bleeding or recurrent miscarriages. As far as uterine cavity 
assessed on ultrasound is normal, hysteroscopy should not 
be used as a first line screening tool in infertility workup or 
before in vitro fertilization procedure [20].
Ultrasound methods of tubal patency 
investigation
Hysterosalpingo-contrast-sonography (HyCoSy) was 
introduced as an alternative to hysterosalpingography (HSG) 
for outpatient tubal assessment. It overcomes such major 
drawbacks as hospitalization, radiation exposure and the 
use of iodinated contrast media.
Figure 2. A. 3D sonohysterography; B. Uterine volume estimation 
using SonoHysteroAVC technique V = 2.5 mL
A B
456
Ginekologia Polska 2021, vol. 92, no. 6
www. journals.viamedica.pl/ginekologia_polska
The most accessible contrast is saline, or a mixture of 
air and saline administered simultaneously or alternately. 
Subsequently, more hyperechoic contrast media were in-
troduced, e.g., Echovist® (galactose microparticles; Schering, 
AG, Berlin, Germany), SonoVue® (sulfur hexafluoride; Bracco, 
Milan, Italy) However, their use is limited because of a high 
cost or no license for an intrafallopian tube. In 2007, a mi-
cro-bubble contrast agent known as ExEm Foam® (Gynaeco-
logIQ, Deft, The Netherlands), containing hydroxyethylcellu-
lose and glycerol was launched [21]. Owing to good quality 
sonograms obtained and acceptable price, hysterosalpin-
go-foam-sonography (HyFoSy) has become widely adopted 
in infertility office and ambulatory settings [22]. 
According to the National Institute for Health and Clini-
cal Excellence (NICE), HyCoSy may be as effective as HSG for 
diagnosing fallopian tube occlusion, and both appear to have 
high sensitivity and specificity compared with laparoscopy 
[23]. NICE, ESHRE, and PTMRiE recommend that it should 
be offered to women with no comorbidities suggesting pel-
vic pathology, such as pelvic inflammatory disease, previous 
ectopic pregnancy or endometriosis [5, 23, 24]. Regarding 
different contrast media, it seems that high negative predic-
tive value (99.5%) of air/saline-HyCoSy suggests that this 
procedure can be implemented as a screening examination. 
Nevertheless, HyCoSy requires greater experience and is 
observer-dependent, since the window for visualizing the 
passage of contrast through the tubes is short [25]. Rapid 
movements of the probe are necessary for tracing the circu-
itous or distant tubes in different planes. HyCoSy with more 
hyperechoic contrasts, e.g., HyFoSy, may be an alternative as 
the foam fills slowly, the tube and remains stable for at least 
5–7 minutes. In addition to this, the use of hyperechoic con-
trast media does not require a learning period as observed 
in series for air/saline-HyCoSy [26]. HyFoSy having a signifi-
cantly higher positive predictive value (30.4% air/saline Hy-
CoSy vs 48% HyFoSy), is suggested a second-step technique 
in the event of e.g., inconclusive examination, occlusion 
suspicion or poor images quality [27].  Additional scanning 
using high-definition flow Doppler further improves the 
accuracy of HyFoSy. According to research of Ludwin et al. 
(2017) [27], it was the only method (with the accuracy of 
95.8%) that did not differ significantly concerning accuracy 
from laparoscopy with dye chromotubation as the reference 
method. According to Chinese data 4D-HyCosy represents 
also highly useful method for diagnosing tubal patency 
[28, 29]. Though in recent meta-analysis its diagnostic per-
formance is similar to 2D-HyCoSy [30]. Certainly, future pro-
spective studies comparing both technics in the same set of 
patients will give more precise answer. Finally, laparoscopy is 
dedicated to patients when hysterosalpingography remains 
inconclusive or as a first line diagnostic tool when pelvic 
pathology influencing the tubes patency is suspected [5].
A tubal patency exam should be carried in the pre-
ovulatory phase. The eventual antibiotic prophylaxis is left 
to examiner’s decision as there are still no guidelines, nor 
randomized controlled trials addressing this issue [31]. 
HyCoSy was reported to be associated with very low risk 
of infections. In fact, post-procedural infections were re-
corded in 0.95% of patients undergoing HyCoSy and were 
absent in HyFoSy studies [32]. An echogenic medium is 
injected transcervically using a balloon catheter (diameter 
5–8 French) or non-balloon dedicated cervical applicator 
[21]. After confirming the correct placement of the catheter, 
contrast is slowly injected into the endometrial cavity and in 
meantime its flow is observed in 2D transverse plane from 
uterine horn, through each tube until peritoneal spill is visu-
alized (Fig. 3A–B). Additional scanning using high-definition 
flow Doppler is beneficial, as it improves the accuracy of the 
exam. The advantage of hyperechoic contrasts is maintain-
ing echogenicity for few minutes; therefore, it allows 3D 
volume acquisition and visualization of the tubal course in 
the coronal view (Fig. 4A–B).
In a randomized controlled trial by Dreyer, HyFoSy 
turned out to be a less painful and less time-consuming 
tubal patency test compared with HSG [32]. Prophylactic 
analgesia is unnecessary, however, it is nevertheless con-
sidered, indomethacin trans-rectally and paracetamol or 
codeine orally seems to be effective [33, 34]. Lately, intra-
uterine lidocaine flushing before HyFoSy has been proven 
Figure 3. 2D HyFoSy; A. Foam visible in interstitial part, isthmus and 
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to decrease the pain during the procedure [35]. In a study 
of 632 women who underwent HyCoSy, no late complica-
tions were observe. Only 6.48% of the patient popula-
tion experienced severe pelvic pain and 4.11% showed 
mild vasovagal reactions [36]. Even lower percentage of 
complications — 0.32%, including vasovagal reactions 
and mild urinary infection, were reported after HyFoSy. 
The median visual analogue scale (VAS) score for percep-
tion of pain was 2 (range 0–10), 1.9% of women reported 
severe pain. Recently, two cases of foam intravasation were 
reported in the literature [37, 38]. In 2019, U. S. Food and 
Drug Administration (FDA) approved HyFoSy for the detec-
tion of fallopian tube patency in women with known or 
suspected infertility [39].
So far, only observational studies investigating the 
chance of subsequent pregnancy after HyCoSy and HyFoSy, 
are available. Cautious conclusions that fertility enhancing 
effect may exist were drawn [40]. More is known about the 
effect of HSG [41]. A recent meta-analysis showed that tubal 
flushing using oil-based contrast medium compared with 
water-based contrast medium and no intervention, prob-
ably increases clinical pregnancy rates within six months 
after randomization and may increase subsequent live-birth 
rates. However, the authors stated that evidence on fertility 
outcomes beyond six months is inadequate to draw firm 
conclusions [41]. This year first research on oil-based con-
trast Lipiodol® (Guerbet LLC, Princeton, New Jersey, USA), 
previously used in HSG, utilization in HyCoSy was published. 
According to Zen et al., sonographic visualization of the agi-
tated Lipiodol is similar or better than that of agitated saline 
[42]. We are waiting for the results of a large, randomized 
study — the FOAM study, which is currently ongoing. The 
researchers want to compare the effectiveness and costs 
of management guided by HyFoSy or by HSG. The primary 
outcome is ongoing pregnancy leading to live birth within 
12 months after randomization [43].
FeRTIlITy SCAN
In 2011 Hrehorcak and Nargund described the idea of 
‘one-stop’ fertility assessment [1]. The concept is focused 
on the investigation both anatomy and function of the 
ovaries and the uterus, as well as the tubes during one visit 
in infertility workup between days 10–12 of a regular cycle. 
To yield the best results the equipment should be of high 
resolution with sensitive color and spectral Doppler modali-
ties and preferably 3D facilities. It is carried out in one place, 
saving the couple and the professional valuable time and is 
66% less expensive. It offers a quick, one hour diagnosis in 
comparison to 18 weeks, on average, of standard multi-visit 
workup [1]. Lately, fertility scan including sonohysterogra-
phy and HyFoSy, called Fertiliscan©, has been proposed [44].
SUMMARy
A diagnostic strategy has to be safe, noninvasive, well 
tolerated and possibly at a low cost for the health care 
system. For these reasons, ultrasound fertility assessment is 
an accurate choice for the first line in the infertility workup 
and its use has been rising.
Performing fertility scan, it is advised to count AFC 
manually using any of the following techniques: real-time 
2D TVS, 2D cine-loops, or 3D TVS datasets. The 2D ultra-
sound is used as a screening tool to assess the uterine cav-
ity. The 3D-TVS and 3D-SIS are recommended as an opti-
mal diagnostic tool in women suspected to have a uterine 
anomaly. HyCoSy and HyFoSy has proved to be a safe and 
well tolerated outpatient procedure in the assessment of 
tubal patency. Air/saline-HyCoSy is considered a screening 
examination, whereas HyFoSy is suitable for a second-step 
technique. Further research should concern the diagnostic 
value of new ultrasound modalities, e.g., 4D-HyCoSy.
The new concepts of ‘one-stop’ fertility scan, combining 
all tests in one, seems to be extremely beneficial to infertile 
couples regarding their fertility potential and stress. One 
stop fertility diagnosis has high demands on the clinic 
logistic, high quality ultrasound equipment and clinics 
ultrasound expertise. Above all, we believe that this is 
the right direction for the future infertility diagnostics 
improvement. 
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